Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood
2024 · The Journal of Infectious Diseases · 11 citations
https://doi.org/10.1093/infdis/jiae530